Emergent BioSolutions said on Monday it would donate 50,000 doses of its vaccine, ACAM2000, to the Democratic Republic of the Congo and other impacted countries of Burundi, Kenya, Rwanda and Uganda to address the current mpox outbreak.
Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS stock rally is likely driven by its smallpox vaccine, ACAM2000, which has potential implications for monkeypox. Potential refinancing and strategic turnaround efforts mitigate the company's financial challenges, including significant debt and cash burn.
The European Centre for Disease Prevention and Control raised its risk level for mpox on Friday. The World Health Organization declared a global public health emergency on Wednesday.
On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million.
Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Emergent BioSolutions said on Monday Johnson & Johnson has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter's COVID-19 vaccine.
Nvidia Corp NVDA is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators.